PMID- 36311684
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221102
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 24
IP  - 6
DP  - 2022 Dec
TI  - Survival outcomes in patients with T3-4aN0M0 glottic laryngeal squamous cell 
      carcinoma and evaluation of postoperative radiotherapy.
PG  - 434
LID - 10.3892/ol.2022.13554 [doi]
LID - 434
AB  - This study aimed to evaluate the clinical outcomes of patients with T3-4aN0M0 
      glottic laryngeal squamous cell carcinoma (LSCC) treated with laryngectomy, and 
      to assess the postoperative radiotherapy (PORT) results in terms of the survival 
      of T3-T4aN0M0 patients with negative margins. This was a retrospective review of 
      369 T3-4aN0M0 glottic LSCC cases. The 5-year cancer-specific survival (CSS) and 
      overall survival (OS) rates were 67.5 and 66.7%, respectively. Patients who 
      received total laryngectomy had worse survival [5-year CSS, 62.5%; disease-free 
      survival (DFS), 56.2%] than those who underwent partial laryngectomy (5-year CSS, 
      79.3%; DFS, 65.4%). More advanced-stage cancer is a predictor of poor survival. 
      There was no significant difference in CSS or DFS between patients with positive 
      margins following rescue therapy and those with negative margins. Furthermore, no 
      difference in the survival rates was observed between patients with negative 
      margins who received PORT and those who did not (5-year DFS: 59.1 vs. 63.8%, 
      P=0.057 and CSS: 62.5 vs. 69.5%, P=0.074). For T3-4aN0M0 glottic LSCC patients, 
      surgical treatment remained a good option, as it can achieve satisfactory 
      oncological outcomes. However, PORT did not increase survival in surgically 
      managed pT3-4aN0M0 LSCC patients with negative margins.
CI  - Copyright: (c) Zhou et al.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Heng, Yu
AU  - Heng Y
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Yang, Yue
AU  - Yang Y
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Zhu, Xiaoke
AU  - Zhu X
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Zhou, Liang
AU  - Zhou L
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Gong, Hongli
AU  - Gong H
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Xu, Chengzhi
AU  - Xu C
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
FAU - Tao, Lei
AU  - Tao L
AD  - Department of Otolaryngology, Eye, Ear, Nose and Throat Hospital, Fudan 
      University, Shanghai 200031, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20221019
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC9608082
OTO - NOTNLM
OT  - T3-4aN0M0
OT  - laryngeal squamous cell carcinoma
OT  - postoperative radiotherapy
OT  - surgery
OT  - survival outcomes
COIS- The authors declare that they have no competing interests.
EDAT- 2022/11/01 06:00
MHDA- 2022/11/01 06:01
PMCR- 2022/10/19
CRDT- 2022/10/31 04:25
PHST- 2022/06/23 00:00 [received]
PHST- 2022/09/30 00:00 [accepted]
PHST- 2022/10/31 04:25 [entrez]
PHST- 2022/11/01 06:00 [pubmed]
PHST- 2022/11/01 06:01 [medline]
PHST- 2022/10/19 00:00 [pmc-release]
AID - OL-24-06-13554 [pii]
AID - 10.3892/ol.2022.13554 [doi]
PST - epublish
SO  - Oncol Lett. 2022 Oct 19;24(6):434. doi: 10.3892/ol.2022.13554. eCollection 2022 
      Dec.